Has Tamim Nazif, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,241,277 in general payments to Tamim Nazif, MD across 635 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tamim Nazif, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tamim Nazif, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tamim Nazif, MD

Cardiovascular Disease · New York, NYNPI 1942323944

Payments from drug & device makers

$2,241,277in general payments, 2019–2025

Across 635 payments — averaging $3529.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$1.2M
Boston Scientific$688K
Medtronic$261K
Abbott$40K
Biotrace Medical, Inc.$14K
Baylis Medical Company Inc$9K
plus $11K from 23 others

$5,772in research payments, 2019–2025

Across 12 payments — averaging $481.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$6K

What the payments were for

Consulting fees$76,26347%
Speaking & faculty fees$16,79910%
Travel & lodging$52,13732%
Food & beverage$16,67710%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	353	$1,218,490
Boston Scientific	125	$688,031
Medtronic(2 entities)	70	$260,913
Abbott	26	$39,553
Biotrace Medical, Inc.	3	$13,600
Baylis Medical Company Inc	4	$9,450
Shockwave Medical, Inc	6	$3,960
Terumo Medical Corporation	5	$2,137
Opsens Inc.	1	$1,750
Arrow International, Inc.	2	$1,332
Teleflex LLC	3	$365
Merit Medical Systems Inc	1	$325
Siemens Medical Solutions USA, Inc.	2	$292
Abiomed	2	$178
Boehringer Ingelheim	10	$173
Bolton Medical Inc	1	$130
Acist Medical Systems, Inc.	1	$124
Amgen	5	$85
Cardiva Medical, Inc.	1	$78
Novartis	2	$49
AstraZeneca	2	$42
Pfizer	1	$38
Kiniksa Pharmaceuticals International, PLC	2	$38
Alnylam Pharmaceuticals Inc.	1	$32
Johnson & Johnson	2	$31
Heartflow, Inc.	1	$24
Cardiovascular Systems Inc.	1	$21
Tactile Systems Technology Inc	1	$21
E.r. Squibb & Sons, L.L.C.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Edwards SAPIEN 3 Transcatheter Heart Valve$26,277
GENERAL - STRUCTURAL HEART$9,910
NRG needle$6,000
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$3,846
WATCHMAN Access System$3,273
VersaCross Access Solution$3,000
GENERAL - THERAPIES$2,861
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$2,240
ANGIO-SEAL$2,000
SavvyWire$1,750
CoreValve Evolut$1,607
HeartMate PHP$1,500
Portico Transcatheter Aortic HV$1,000
SAPIEN 3 Ultra RESILIA$825
ISLEEVE$467
GUIDEWIRES$300
COREVALVE EVOLUT R$238
Optis Coronary Imaging System$179
PASCAL$165
OPTICROSS$150

How this compares

$2,241,277 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York →

Medicare billing

Part B allowed, 2024

$176,189

Medicare patients

285

Services billed

743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ClopidogrelClopidogrel Bisulfate	16	$112
Atorvastatin Calcium	12	$84

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New York

James MinNew York$41.1M
Robert RosensonNew York$6.9M
Roxana MehranNew York$6.4M
Roger HajjarNew York$5.2M
Philippe GenereuxNew York$4.4M
Gregg StoneNew York$3.7M
Valentin FusterNew York$2.9M
Howard WeintraubNew York$1.7M
Anuradha Lala-TrindadeNew York$1.5M
Cezar StaniloaeNew York$1.2M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →